CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00415-07v1
15/3/484    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Kraiczy, P.
Right arrow Articles by Stevenson, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraiczy, P.
Right arrow Articles by Stevenson, B.
Clinical and Vaccine Immunology, March 2008, p. 484-491, Vol. 15, No. 3
1071-412X/08/$08.00+0     doi:10.1128/CVI.00415-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Borrelia burgdorferi Complement Regulator-Acquiring Surface Protein 2 (CspZ) as a Serological Marker of Human Lyme Disease{triangledown}

Peter Kraiczy,1,{dagger} Annekatrin Seling,1,{dagger} Catherine A. Brissette,2 Evelyn Rossmann,3 Klaus-Peter Hunfeld,1 Tomasz Bykowski,2,{ddagger} Logan H. Burns,2 Matthew J. Troese,2,§ Anne E. Cooley,2 Jennifer C. Miller,2, Volker Brade,1 Reinhard Wallich,3 Sherwood Casjens,4 and Brian Stevenson2*

Institute of Medical Microbiology and Infection Control, University Hospital of Frankfurt, Frankfurt am Main, Germany,1 Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky College of Medicine, Lexington, Kentucky,2 Department of Immunology, University of Heidelberg, Heidelberg, Germany,3 Department of Pathology, University of Utah Medical School, Salt Lake City, Utah4

Received 15 October 2007/ Returned for modification 19 November 2007/ Accepted 14 December 2007


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Serological diagnosis of Lyme disease may be complicated by antigenic differences between infecting organisms and those used as test references. Accordingly, it would be helpful to include antigens whose sequences are well conserved by a broad range of Lyme disease spirochetes. In the present study, line blot analyses were performed using recombinant complement regulator-acquiring surface protein 2 (BbCRASP-2) from Borrelia burgdorferi sensu stricto strain B31 and serum samples from human Lyme disease patients from throughout the United States and Germany. The results indicated that a large proportion of the patients had produced antibodies recognizing recombinant BbCRASP-2. In addition, Lyme disease spirochetes isolated from across North America and Europe were found to contain genes encoding proteins with high degrees of similarity to the B. burgdorferi type strain B31 BbCRASP-2, consistent with the high percentage of serologically positive patients. These data indicate that BbCRASP-2 may be valuable for use in a widely effective serological assay.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Lyme disease (Lyme borreliosis) is the most prevalent tick-borne disease affecting humans in the United States, Europe, and a broad swath across Asia (18, 46, 62). Symptoms of human Lyme disease generally include nonspecific "flu-like" complaints, such as fever and body aches, and may or may not include problems such as skin rashes and lesions, arthritis, and neurological or cardiac difficulties (62). Genetic analyses of the causative agent, the spirochete Borrelia burgdorferi sensu lato, have divided that species into a number of genovars or genospecies, including B. burgdorferi sensu stricto, B. garinii, B. afzelii, B. spielmanii, B. bissettii, and others (7, 49, 52, 62, 77). Results of several studies have indicated associations between certain borrelial genospecies and particular Lyme disease symptoms (4, 6, 8, 37, 47, 55, 68, 71, 75, 77, 81). The range of symptoms that may be seen with each patient often complicates clinical diagnosis of Lyme disease. In addition, genetic variations among Lyme disease spirochetes pose difficulties for the development of widely useful serological tools for identifying infected individuals. For example, the outer surface protein OspC is produced by B. burgdorferi sensu lato during the initial stages of mammalian infection and is the target of a strong humoral immune response, but ospC gene sequences differ considerably among Lyme disease borreliae, even among bacteria within the same geographic location (36, 59, 64, 69, 78, 79). Identification of highly antigenic borrelial proteins whose sequences are well conserved across genospecies and geographic areas will be very important for development of improved serological tools for diagnosis of Lyme disease.

Our laboratories, and others, have been investigating mechanisms used by B. burgdorferi sensu lato to avoid killing by its hosts' immune systems during vertebrate infection. Resistance to the alternative pathway of complement activation appears to be facilitated, in part, by binding host complement regulatory proteins, such as factor H, factor H-like protein 1 (FHL-1), and factor H-related proteins to the bacterial outer surface (3, 25, 32-34, 39, 80). Borrelial proteins that serve those functions have been designated CRASPs (complement regulator-acquiring surface proteins) (34). Different borrelial genospecies appear to produce different CRASPs, so the proteins of B. burgdorferi sensu stricto are often referred to as BbCRASPs and those of B. afzelii are called BaCRASPs, etc. (27, 34). Intriguingly, very few isolates of B. garinii have been found to produce CRASPs during laboratory cultivation, and so little is known about how that bacterium evades clearance by its vertebrate hosts (1, 34).

Three genetically distinct classes of BbCRASPs have been identified. BbCRASP-1, encoded by the cspA gene, is produced by B. burgdorferi sensu stricto only during tick-to-mammal and mammal-to-tick transmission stages (12, 15, 19, 28, 35, 72). Presumably as a consequence of the short duration of BbCRASP-1 expression during mammalian infection, humans do not produce robust levels of antibodies against that protein (38, 54). Another class of BbCRASPs, members of the Erp protein family, including ErpA (BbCRASP-5), ErpC (BbCRASP-4), ErpP (BbCRASP-3), and OspE are produced throughout mammalian infection and are consistent targets of host antibody production (2, 25, 26, 29, 31, 40, 42, 44, 45, 66, 67). However, sequences of those proteins often vary widely between bacteria, limiting their usefulness for serodiagnosis (41, 66). The third known type of B. burgdorferi sensu stricto factor H/FHL-1 binding protein, BbCRASP-2, was recently identified as being encoded by the cspZ gene (24). BbCRASP-2 is highly expressed during mammalian infection (15). Our preliminary investigations demonstrated that laboratory-infected mice produce antibodies against BbCRASP-2 within 4 weeks of infection (24). In the present work, serum samples obtained from human Lyme disease patients in the United States and Germany who manifested a range of disease symptoms were examined for the presence of BbCRASP-2-directed antibodies. Sequences of cspZ genes were also determined for a variety of borrelial strains of different genospecies. Our results indicate that cspZ sequences are well conserved among Lyme disease borreliae independently of their geographic distribution and that antibodies recognizing BbCRASP-2 are frequently produced by humans with Lyme disease.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Bacteria. Strains of B. burgdorferi sensu lato used in these studies are listed in Table 1. Borrelial strains were grown at 33°C to cell densities of approximately 1 x 107/ml in either modified Barbour-Stoenner-Kelly medium or Barbour-Stoenner-Kelly-H complete medium (Sigma-Aldrich, St. Louis, MO) as described previously (21, 31, 83).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Borrelia spp. strains used in this work

 
Serological analyses. Preexisting human Lyme disease and control serum samples were kindly provided by Martin Schriefer (U.S. Centers for Disease Control and Prevention, Fort Collins, CO), Gary Wormser (New York Medical College, Valhalla, NY), the University Hospital of Frankfurt, or the blood bank of Frankfurt, Germany. Human control samples consisted of sera obtained from healthy blood donors (n = 10) and from patients with active or recent primary syphilis (n = 10), leptospirosis (n = 15), human immunodeficiency virus (HIV; n = 15), antinuclear antibodies (n = 15), or rheumatoid arthritis (n = 15). U.S. serum samples were from clinically diagnosed patients and have been used in previous serological studies (41, 43). German serum samples obtained from Lyme disease patients and from the control groups were pretested for the presence of anti-borrelia immunoglobulin G (IgG) antibodies using a commercially available line immunoblot assay (Genzyme Virotech, Rüsselsheim, Germany) in which VlsE, BmpA, p83, BBA36, BBO323, BbCRASP-3 (ErpP), and pG (ErpG) are included as target antigens. Additional positive control sera were obtained 4 weeks postinfection from four mice that had been infected with B. burgdorferi sensu stricto strain B31 by infestation with infected Ixodes scapularis ticks (44).

Recombinant BbCRASP-2 protein was produced based on the sequence of B. burgdorferi sensu stricto strain B31 (24). For line blotting, recombinant BbCRASP-2 was transferred to nitrocellulose membranes by a microdispensing method in amounts of 32, 16, 8, 4, 2, 1, or 0.1 ng per stripe. Individual membranes were incubated with human sera (German sera at 1:100 and U.S. sera at 1:200) or mouse sera (1:100). Serum dilutions were based upon serological studies with other borrelial antigens (see above). Binding of specific antibodies was detected by using alkaline phosphatase-conjugated goat anti-human IgG serum (1:100; Genzyme Virotech) or goat anti-mouse Ig antibodies (1:10,000; GE Healthcare, Little Chalfont, United Kingdom), as appropriate. Immunoreactive bands were visualized by addition of 3 ml of diethanolamine buffer supplemented with 5-bromo-4-chloro-3-indolylphosphate (Sigma-Aldrich) at 165 µg/ml and nitroblue tetrazolium (Sigma-Aldrich) at 330 µg/ml as a substrate.

cspZ sequencing. The cspZ gene sequence of B. burgdorferi sensu stricto type strain B31 (open reading frame BBH06) was previously determined as part of the genome sequencing project for that bacterium (16, 21). The cspZ genes from B. burgdorferi sensu stricto strains BL206, 93-0117, CA15, LW2, 2307/5, ZS5, N40, 124a, 297, and Sh-2-82 were amplified from total purified bacterial plasmids using oligonucleotides CSPZ-1 and CSPZ-2 (Table 2). Sequences of those two oligonucleotides were based upon DNA sequences located 5' and 3' of the strain B31 cspZ open reading frame, respectively, and thereby amplified the entire cspZ gene plus additional, flanking DNAs. The cspZ genes of B. garinii strain Ip89 and B. spielmanii strain A14S were PCR amplified from purified plasmid DNAs using oligonucleotide primers CSPZ-5 and CSPZ-4 (Table 2), which are based upon sequences located within the strain B31 cspZ open reading frame, near the 5' and 3' ends, respectively. Amplicons were either purified using Centricon-100 filters (20) and then sequenced without cloning or were cloned into pCR2.1 (Invitrogen, Carlsbad, CA) and subsequently sequenced.


View this table:
[in this window]
[in a new window]

  		TABLE 2. Oligonucleotides used in this study

 
The 5' end of the B. garinii Ip89 cspZ gene was cloned by first digesting Ip89 total plasmid DNAs with HindIII, self-ligating that DNA using T4 DNA ligase, and then performing PCR amplification with oligonucleotide primers CSPZ-6 and CSPZ-7. Those primers direct the PCR outward from the cspZ gene. The resulting amplicon was cloned into pCR2.1 and then sequenced.

The cspZ locus sequences of B. burgdorferi strains JD1, 156a, and ZS7 and B. bissettii strain DN127 were extracted from unpublished whole-genome sequences of those bacteria. B. afzelii strains were examined for the presence of cspZ loci by BLAST-P and BLAST-N analyses of GenBank (http://www.ncbi.nlm.nih.gov/BLAST/) and searches of the published partial genome of B. afzelii strain PKo (23) and of the completed, unpublished whole-genome sequences of B. afzelii strains PKo and ACA (S. Casjens, unpublished data). The B. garinii strain PBi cspZ gene sequence was identified in GenBank by BLAST-P analysis using the strain B31 BbCRASP-2 protein sequence as the query. The strain PBi cspZ gene is within the deposited DNA segment G11a14a06.r1 (accession number AY722931), an unassembled plasmid fragment of strain PBi that was sequenced during a partial sequence analysis of that strain (22).

DNA sequences were analyzed using the DNA Strider 1.4f8 (cmarck@cea.fr) or DNAstar Lasergene 99 (Madison, WI) program. Predicted amino acid sequences were compared and aligned using Clustal X (70) with default parameter settings.

Nucleotide sequence accession numbers. The sequences of the cspZ loci from B. burgdorferi sensu stricto strains BL206, CA15, LW2, 2307/5, Z25, 93-0117, N40, 124a, 297, and Sh-2-82 have been assigned accession numbers EU272843 through EU272852, respectively. The cspZ locus of B. garinii strain Ip89 has accession number EU272853, and that of B. spielmanii strain A14S has accession number U272854.

(Parts of this work form parts of the M.D. thesis of Annekatrin Seling.)


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Serological examination of human Lyme disease patient sera. Our earlier investigations, using the mouse model of Lyme disease, discovered that B. burgdorferi produced elevated levels of cspZ transcript within 2 weeks of infecting mammals and that mice seroconverted within 4 weeks of infection (the earliest time points examined) (15, 24). Those data suggested that human patients are probably also exposed to BbCRASP-2 during the early stages of Lyme disease. To evaluate that hypothesis and to explore the potential usefulness of BbCRASP-2 as a serodiagnostic antigen, we examined serum samples from patients diagnosed with Lyme disease in Germany and from several locations across the United States. Patients had exhibited a range of symptoms, including erythema migrans, arthritis, acrodermatitis chronica atrophicans (ACA), and neuroborreliosis. As noted above, several of those Lyme disease manifestations are associated with specific Borrelia genospecies (4, 6, 8, 37, 47, 55, 68, 71, 75, 77, 81). In this manner, we sought to examine patients likely to have been infected with a range of different borrelial genospecies and varieties within those species. Moreover, sera were collected from some patients within 1 day of symptom appearance, allowing us to examine whether or not humans seroconvert during early stages of Lyme disease.

The human serum samples were analyzed by immunoblotting with nitrocellulose strips containing various amounts of recombinant B. burgdorferi strain B31 BbCRASP-2. The use of different amounts of BbCRASP-2 allowed optimization of both sensitivity and specificity. All examined patients with erythema migrans, ACA, or Lyme arthritis yielded immunoblot signals when 16 ng recombinant BbCRASP-2 was examined, and many patient samples provided strong signals from much less test antigen (Fig. 1A to F; Table 3). Sera from 80% of tested neuroborreliosis patients also gave a positive signal against 16 ng BbCRASP-2. Patients from both the United States and Germany produced BbCRASP-2-binding antibodies. Consistent with the observed early expression of BbCRASP-2 during murine infection (15), strong immunoblot signals were obtained with sera taken from patients within 1 to 3 days of the appearance of symptoms (Fig. 1A). Mice experimentally infected with B. burgdorferi sensu stricto strain B31 via tick bite all produced high levels of BbCRASP-2-directed antibodies (Fig. 1G), while uninfected mice did not contain detectable levels of such antibodies (data not shown) (24).


Figure 1
View larger version (68K):
[in this window]
[in a new window]

  		FIG. 1. Line blot analyses of human patient sera for antibodies recognizing BbCRASP-2. Nitrocellulose membrane strips contained stripes of recombinant BbCRASP-2 in amounts of 32, 16, 8, 4, 2, 1, and 0.1 ng (top of strip to bottom). Many of the patient serum samples from the United States have been used in previous analyses of other borrelial antigens (41, 43), and their designations are presented here for cross-referencing. (A) Paired serum samples from acute and convalescent patients diagnosed with erythema migrans in New York. Numbers above each blot indicate numbers of days between initial diagnosis and collection of serum sample. Pair 1, NY 96-1087 and 96-1088; pair 2, NY 96-1049 and 96-1050; pair 3, NY 96-1077 and 96-1078. A biopsy of the patient who provided serum samples NY 96-1087 and -1088 yielded B. burgdorferi strain 124a, the cspZ gene of which was sequenced, and the predicted BbCRASP-2 amino acid sequence is presented in Fig. 2, below. (B) Acute-phase serum samples from patients diagnosed with erythema migrans at various locations in the United States. The sample designations and reported durations of infection prior to sample collection are as follows: lane 1, NY-2, 30 days; lane 2, NY-3, 30 days; lane 3, NY-5, 30 days; lane 4, NY-6, 30 days; lane 5, NY-7, 30 days; lane 6, NY-8, 30 days; lane 7, CA 92-1682, 1 day; lane 8, WI-93-0206, 86 days; lane 9, WI 93-1414, 5 days. A biopsy of the patient who provided serum sample WI 93-0206 yielded B. burgdorferi strain 93-0117, the cspZ gene of which was sequenced, and the predicted BbCRASP-2 amino acid sequence is presented in Fig. 2, below. (C) Serum samples from German patients diagnosed with erythema migrans with a positive Lyme disease serology. (D) Serum samples from German patients diagnosed with facial palsy, meningitis, or Bannwarth's syndrome (neuroborreliosis, stage II) in the Rhein-Main area and Aschaffenburg, Germany. (E and F) Serum samples from German patients with chronic Lyme disease (ACA and arthritis, respectively). (G) Sera collected from mice 4 weeks following their infestation with ticks infected with B. burgdorferi sensu stricto strain B31. (H to M) Serum samples from non-Lyme disease patients and healthy controls, including patients with a positive syphilis serology and an otherwise-negative borrelia serology (H), leptospirosis patients (I), HIV patients (J), persons with antinuclear antibodies (K), and patients with rheumatoid arthritis (L) and serum samples from blood donors, provided by the blood bank of Frankfurt, Germany (M).

 

View this table:
[in this window]
[in a new window]

  		TABLE 3. Results of BbCRASP-2 line blot analyses of human Lyme disease patient and control serum samples

 
Serum samples from control patients, which consisted of healthy blood donors and patients with either syphilis, leptospirosis, HIV, antinuclear antibodies, or rheumatoid arthritis, were almost uniformly negative for the presence of antibodies that bound BbCRASP-2 (Fig. 1H to M; Table 3). Samples from one syphilis patient and one blood donor who were otherwise seronegative for exposure to Lyme disease contained antibodies that recognized some higher concentrations of BbCRASP-2 (Fig. 1H and M; Table 3). These may represent undiagnosed prior exposure to Lyme disease spirochetes or cross-reacting antibodies directed against Treponema pallidum or other sources.

Conservation of cspZ sequences among Lyme disease borreliae. Earlier work from our laboratories identified cspZ of B. burgdorferi sensu stricto strain B31 as encoding BbCRASP-2 (24). Pathogenic strains of B. afzelii and B. spielmanii also produce similarly sized factor H-binding proteins, known as BaCRASP-2 and BsCRASP-2, respectively, although the gene encoding those proteins had not previously been identified (27, 34). In the serological studies described above, it is probable that some of the examined patients were infected with borreliae other than B. burgdorferi sensu stricto, especially the European patients, who are likely to become exposed to other infectious genospecies, such as B. garinii (7, 77). The preponderance of human Lyme disease patients who produced antibodies recognizing BbCRASP-2 suggested a high degree of cspZ sequence conservation among strains and genospecies of Lyme disease spirochetes. To assess that possibility, bacteria isolated from human and tick sources across North America and Eurasia were analyzed for cspZ, and gene sequences were determined. Examined borreliae included members of all the major species known to be infectious to humans.

The B. burgdorferi sensu stricto type strain B31 has been completely sequenced and carries its cspZ gene on a plasmid, lp28-3 (16, 21, 24). Genome sequencing of several additional Lyme disease borreliae is in the final stages of closure, and examination of those sequences reveals that the cspZ locus of those strains is also located on a plasmid related to lp28-3 (S. Casjens, unpublished results). An unavoidable difficulty with analyzing plasmidticular bacterial strain does not necessarily mean that its wild parent lacked the gene.

Through a combination of whole-genome sequencing and PCR using oligonucleotide primer pairs based on DNA sequences flanking or within the cspZ open reading frame of B. burgdorferi sensu stricto strain B31, we identified cspZ genes in the majority of examined strains of B. burgdorferi sensu stricto, as well as in B. spielmanii and B. bissettii (Table 1). Unexpectedly, examination of a B. garinii strain, Ip89, revealed that it too contains a cspZ locus. BLAST analyses of GenBank unearthed the sequence of an unannotated DNA fragment of B. garinii strain PBi that contains a cspZ gene similar to that of strain Ip89. None of the B. afzelii strains we examined carried a cspZ locus. However, while the manuscript was being prepared, another research group reported detection of cspZ genes in two of four tested B. afzelii strains (53). Thus, all the major genospecies associated with human Lyme disease have been found to contain cspZ genes. Alignment of the predicted protein sequences of these cspZ genes revealed extensive similarities throughout the proteins (Fig. 2). High levels of protein identities were evident both within regions determined to be involved with binding factor H and/or FHL-1 and within regions that probably serve more structural roles. Thus, cspZ-encoded proteins are predicted to exhibit conservation of both primary amino acid sequences and higher-order structural elements. These similarities suggest that antibodies targeting both linear and structural epitopes will bind cspZ-encoded proteins from other Lyme disease spirochetes, consistent with our serological studies described above (Fig. 1; Table 3).


Figure 2
View larger version (140K):
[in this window]
[in a new window]

  		FIG. 2. Alignment of predicted amino acid sequences of cspZ-encoded proteins of B. burgdorferi sensu lato strains collected from human and tick sources across the United States and Europe (Table 1). Each strain name is prefixed with its genospecies: Bbu, B. burgdorferi sensu stricto; Bbi, B. bissettii; Bg, B. garinii; Bs, B. spielmanii. Identical amino acids present in the majority of proteins are boxed and shaded. Regions of the B. burgdorferi sensu stricto BbCRASP-2 demonstrated to have affinity for factor H and/or FHL-1 are indicated over the alignments (24). All predicted proteins contain an amino-terminal leader polypeptide and a conserved lipobox cleavage sequence/lipid-accepting cysteine residue (56, 61). The additional amino-terminal residues of each B. garinii cspZ-encoded protein have no apparent effect upon ligand binding (53) and likely function as extended "tethers" that give mature proteins extra flexibility (19, 56).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The present study revealed that a large proportion of tested human Lyme disease patients produce antibodies that recognize the B. burgdorferi sensu stricto strain B31 BbCRASP-2 factor H/FHL-1-binding protein. Analyses of a wide variety of geographically dispersed isolates of Lyme disease Borrelia species revealed very high degrees of cspZ sequence conservation. The examined strains included two cultures of borreliae isolated from human Lyme disease patients who had produced detectable levels of antibodies recognizing the B31 BbCRASP-2 protein (Fig. 1A and B). Serum samples drawn from patients as early as the day of diagnosis contained detectable levels of antibodies that bound BbCRASP-2. Thus, we conclude that, early in human infection, a large proportion of Lyme disease patients mount a detectable humoral immune response to the cspZ-encoded protein produced by the infecting spirochetes. That antigenicity, plus the high degrees of similarities among cspZ genes between genetically and geographically diverse bacteria, suggests that BbCRASP-2, or a portion of that protein, may be a useful antigen for serodiagnosis of Lyme disease.

Some of the serum samples examined from syphilis patients or control blood donors contained antibodies that bound recombinant BbCRASP-2. This suggests that T. pallidum and other organisms may produce proteins having sequence or conformational similarities with BbCRASP-2. Studies are under way to extend our studies using various fragments of BbCRASP-2, to eliminate possible cross-reactive epitopes and increase the specificity of this serological test.

The strong humoral immune responses of infected humans and mice against cspZ-encoded CRASPs are somewhat paradoxical, given the high levels of cspZ expression during mammalian infection (15). Some other antigenic borrelial outer surface proteins are also produced at high levels during persistent infection, including the factor H-binding Erp proteins (44, 45, 65). It remains a mystery how Lyme disease spirochetes persistently infect humans and other mammals despite their production of antibodies against highly expressed borrelial surface proteins such as CRASP-2. Possibilities include characteristics of those proteins such that they preferentially elicit production of nonneutralizing antibodies, the adherence of host factors (such as factor H and FHL-1) blocking recognition by antibodies during infection, or bacterial inhabitation of host tissues that are privileged from the humoral immune system.

An unanticipated finding from these studies was the discovery that bacteria of the genospecies B. garinii contain cspZ genes, encoding proteins that are highly similar to BbCRASP-2. This result was unexpected, in that no examined strain of B. garinii produces a factor H/FHL-1-binding protein of this size when grown in culture (1, 3, 24, 31, 32, 39). This may indicate that B. garinii cspZ-encoded proteins unable to bind human factor H, as recently suggested by Rogers and Marconi (53). Differences among regions known to be involved in factor H/FHL-1-binding support that hypothesis (Fig. 2) (24). As a second possibility, B. garinii and B. burgdorferi sensu stricto may control cspZ expression differently, such that B. burgdorferi sensu stricto produces its protein during cultivation in artificial laboratory media, while B. garinii does not. It has been demonstrated that B. burgdorferi sensu stricto significantly represses cspZ transcription during laboratory cultivation, compared to expression levels during mammalian infection (15). Further supporting that hypothesis, the 5' noncoding regions of B. garinii cspZ loci share little homology with those of B. burgdorferi sensu stricto (data not shown) and may therefore be transcriptionally regulated through distinct mechanisms. Studies are ongoing in our laboratories to evaluate each of these hypotheses.

In conclusion, a majority of tested human Lyme disease patients produced antibodies recognizing BbCRASP-2, while only a small portion of negative control serum samples contained reactive antibodies. Consistent with those serological data, cspZ gene sequences were found to be highly conserved across a broad range of Lyme disease spirochete genospecies. These results demonstrate that Lyme disease borreliae produce cspZ-encoded proteins during human infection and suggest that BbCRASP-2 has potential for use in sensitive and specific serological diagnosis of Lyme disease.


   ACKNOWLEDGMENTS
 
This work was funded by Deutsche Forschungsgemeinschaft grant Kr3383/1-1 to P. Kraiczy and U.S. National Institutes of Health grant R01 AI-44254 to B. Stevenson. Logan Burns was supported in part by U.S. National Institutes of Health Training Grant in Microbial Pathogenesis T32-AI49795.

We thank Richard Marconi and Russell Johnson for providing strains of bacteria; Martin Schriefer, Gary Wormser, the University Hospital of Frankfurt, and the blood bank of Frankfurt, Germany, for providing serum samples; and Christa Hanssen-Hübner, Jane Herrlich, Juri Habicht, Sean Riley, Ashutosh Verma, and Michael Woodman for skillful and expert technical assistance and for comments on the manuscript.


   FOOTNOTES
 
* Corresponding author. Mailing address: Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky College of Medicine, MS 421, W. R. Willard Medical Education Building, Lexington, KY 40536-0298. Phone: (859) 257-9358. Fax: (859) 257-8994. E-mail: brian.stevenson{at}uky.edu Back

{triangledown} Published ahead of print on 26 December 2007. Back

{dagger} P.K. and A.S. contributed equally to the work. Back

{ddagger} Present address: Center for Medical Education, Warsaw, Poland. Back

§ Present address: Dept. of Microbiology and Immunology, Virginia Commonwealth University, Richmond, VA. Back

Present address: Department of Pathology, University of Utah Medical School, Salt Lake City, UT. Back


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Alitalo, A., T. Meri, P. Comstedt, L. Jeffery, J. Tornberg, T. Strandin, H. Lankinen, S. Bergström, M. Cinco, S. R. Vuppala, D. R. Akins, and S. Meri. 2005. Expression of complement factor H binding immunoevasion proteins in Borrelia garinii isolated from patients with neuroborreliosis. Eur. J. Immunol. 35:3043-3053.[CrossRef][Medline]
  2. Alitalo, A., T. Meri, H. Lankinen, I. Seppälä, P. Lahdenne, P. S. Hefty, D. Akins, and S. Meri. 2002. Complement inhibitor factor H binding to Lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs. J. Immunol. 169:3847-3853.[Abstract/Free Full Text]
  3. Alitalo, A., T. Meri, L. Rämö, T. S. Jokiranta, T. Heikkilä, I. J. T. Seppälä, J. Oksi, M. Viljanen, and S. Meri. 2001. Complement evasion by Borrelia burgdorferi: serum-resistant strains promote C3b inactivation. Infect. Immun. 69:3685-3691.[Abstract/Free Full Text]
  4. Anthonissen, F. M., M. De Kesel, P. P. Hoet, and G. H. Bigaignon. 1994. Evidence for the involvement of different genospecies of Borrelia in the clinical outcome of Lyme disease in Belgium. Res. Microbiol. 145:327-331.[Medline]
  5. Asbrink, E., A. Hovmark, and B. Hederstedt. 1984. The spirochetal etiology of acrodermatitis chronica atrophicans Herxheimer. Acta Dermatol. Venereol. 64:506-512.[Medline]
  6. Balmelli, T., and J. C. Piffaretti. 1995. Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato. Res. Microbiol. 146:329-340.[Medline]
  7. Baranton, G., D. Postic, I. Saint Girons, P. Boerlin, J.-C. Piffaretti, M. Assous, and P. A. D. Grimont. 1992. Delineation of Borrelia burgdorferi sensu stricto, Borrelia garinii sp. nov., and group VS461 associated with Lyme borreliosis. Int. J. Syst. Bacteriol. 42:378-383.[CrossRef][Medline]
  8. Baranton, G., G. Seinost, G. Theodore, D. Postic, and D. Dykhuizen. 2001. Distinct levels of genetic diversity of Borrelia burgdorferi are associated with different aspects of pathogenicity. Res. Microbiol. 152:149-156.[Medline]
  9. Barbour, A. G. 1988. Plasmid analysis of Borrelia burgdorferi, the Lyme disease agent. J. Clin. Microbiol. 26:475-478.[Abstract/Free Full Text]
  10. Barthold, S. W., K. D. Moody, G. A. Terwilliger, P. H. Duray, R. O. Jacoby, and A. C. Steere. 1988. Experimental Lyme arthritis in rats infected with Borrelia burgdorferi. J. Infect. Dis. 157:842-846.[Medline]
  11. Bissett, M. L., and W. Hill. 1987. Characterization of Borrelia burgdorferi strains isolated from Ixodes pacificus ticks in California. J. Clin. Microbiol. 25:2296-2301.[Abstract/Free Full Text]
  12. Brooks, C. S., S. R. Vuppala, A. M. Jett, A. Alitalo, S. Meri, and D. R. Akins. 2005. Complement regulator-acquiring surface protein 1 imparts resistance to human serum in Borrelia burgdorferi. J. Immunol. 175:3299-3308.[Abstract/Free Full Text]
  13. Bunikis, J., U. Garpmo, J. Tsao, J. Berglund, D. Fish, and A. G. Barbour. 2004. Sequence typing reveals extensive strain diversity of the Lyme borreliosis agents Borrelia burgdorferi in North America and Borrelia afzelii in Europe. Microbiology 150:1741-1755.[Abstract/Free Full Text]
  14. Burgdorfer, W., A. G. Barbour, S. F. Hayes, J. L. Benach, E. Grunwaldt, and J. P. Davis. 1982. Lyme disease—a tick-borne spirochetosis? Science 216:1317-1319.[Abstract/Free Full Text]
  15. Bykowski, T., M. E. Woodman, A. E. Cooley, C. A. Brissette, V. Brade, R. Wallich, P. Kraiczy, and B. Stevenson. 2007. Coordinated expression of Borrelia burgdorferi complement regulator-acquiring surface proteins during the Lyme disease spirochete's mammal-tick infection cycle. Infect. Immun. 75:4227-4236.[Abstract/Free Full Text]
  16. Casjens, S., N. Palmer, R. van Vugt, W. M. Huang, B. Stevenson, P. Rosa, R. Lathigra, G. Sutton, J. Peterson, R. J. Dodson, D. Haft, E. Hickey, M. Gwinn, O. White, and C. Fraser. 2000. A bacterial genome in flux: the twelve linear and nine circular extrachromosomal DNAs of an infectious isolate of the Lyme disease spirochete Borrelia burgdorferi. Mol. Microbiol. 35:490-516.[CrossRef][Medline]
  17. Casjens, S., R. van Vugt, K. Tilly, P. A. Rosa, and B. Stevenson. 1997. Homology throughout the multiple 32-kilobase circular plasmids present in Lyme disease spirochetes. J. Bacteriol. 179:217-227.[Abstract/Free Full Text]
  18. Centers for Disease Control and Prevention. 2007. Lyme disease—United States, 2003-2005. Morbid. Mortal. Wkly. Rep. 56:573-576.
  19. Cordes, F. S., P. Roversi, P. Kraiczy, M. M. Simon, V. Brade, O. Jahraus, R. Wallis, C. Skerka, P. F. Zipfel, R. Wallich, and S. M. Lea. 2005. A novel fold for factor H-binding protein BbCRASP-1 of Borrelia burgdorferi. Nat. Struct. Mol. Biol. 12:276-277.[CrossRef][Medline]
  20. El-Hage, N., L. D. Lieto, and B. Stevenson. 1999. Stability of erp loci during Borrelia burgdorferi infection: recombination is not required for chronic infection of immunocompetent mice. Infect. Immun. 67:3146-3150.[Abstract/Free Full Text]
  21. Fraser, C. M., S. Casjens, W. M. Huang, G. G. Sutton, R. Clayton, R. Lathigra, O. White, K. A. Ketchum, R. Dodson, E. K. Hickey, M. Gwinn, B. Dougherty, J.-F. Tomb, R. D. Fleischmann, D. Richardson, J. Peterson, A. R. Kerlavage, J. Quackenbush, S. Salzberg, M. Hanson, R. van Vugt, N. Palmer, M. D. Adams, J. Gocayne, J. Weidmann, T. Utterback, L. Watthey, L. McDonald, P. Artiach, C. Bowman, S. Garland, C. Fujii, M. D. Cotton, K. Horst, K. Roberts, B. Hatch, H. O. Smith, and J. C. Venter. 1997. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 390:580-586.[CrossRef][Medline]
  22. Glöckner, G., R. Lehmann, A. Romualdi, S. Pradella, U. Schulte-Spechtel, M. Schilhabel, B. Wilske, J. Sühnel, and M. Platzer. 2004. Comparative analysis of the Borrelia garinii genome. Nucleic Acids Res. 32:6038-6046.[Abstract/Free Full Text]
  23. Glöckner, G., U. Schulte-Spechtel, M. Schilhabel, M. Felder, J. Suehnel, B. Wilske, and M. Platzer. 2006. Comparative genome analysis: selection pressure on the Borrelia vls cassettes is essential for infectivity. BMC Genomics 7:211.[CrossRef][Medline]
  24. Hartmann, K., C. Corvey, C. Skerka, M. Kirschfink, M. Karas, V. Brade, J. C. Miller, B. Stevenson, R. Wallich, P. F. Zipfel, and P. Kraiczy. 2006. Functional characterization of BbCRASP-2, a distinct outer membrane protein of Borrelia burgdorferi that binds host complement regulators factor H and FHL-1. Mol. Microbiol. 61:1220-1236.[CrossRef][Medline]
  25. Haupt, K., P. Kraiczy, R. Wallich, V. Brade, C. Skerka, and P. F. Zipfel. 2007. Binding of human FHR-1 to serum resistant Borrelia burgdorferi is mediated by borrelial complement regulator-acquiring surface proteins. J. Infect. Dis. 196:124-133.[CrossRef][Medline]
  26. Hellwage, J., T. Meri, T. Heikkilä, A. Alitalo, J. Panelius, P. Lahdenne, I. J. T. Seppälä, and S. Meri. 2001. The complement regulatory factor H binds to the surface protein OspE of Borrelia burgdorferi. J. Biol. Chem. 276:8427-8435.[Abstract/Free Full Text]
  27. Herzberger, P., C. Siegel, C. Skerka, V. Fingerle, U. Schulte-Spechtel, A. van Dam, B. Wilske, V. Brade, P. F. Zipfel, R. Wallich, and P. Kraiczy. 2007. Human pathogenic Borrelia spielmanii sp. nov. resists complement-mediated killing by direct binding of immune regulators factor H and FHL-1. Infect. Immun. 75:4817-4825.[Abstract/Free Full Text]
  28. Kraiczy, P., J. Hellwage, C. Skerka, H. Becker, M. Kirschfink, M. M. Simon, V. Brade, P. F. Zipfel, and R. Wallich. 2004. Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J. Biol. Chem. 279:2421-2429.[Abstract/Free Full Text]
  29. Kraiczy, P., J. Hellwage, C. Skerka, M. Kirschfink, V. Brade, P. F. Zipfel, and R. Wallich. 2003. Immune evasion of Borrelia burgdorferi: mapping of a complement inhibitor factor H-binding site of BbCRASP-3, a novel member of the Erp protein family. Eur. J. Immunol. 33:697-707.[CrossRef][Medline]
  30. Kraiczy, P., K.-P. Hunfeld, S. Breiner-Ruddock, R. Würzner, G. Acker, and V. Brade. 2000. Comparison of two laboratory methods for the determination of serum resistance in Borrelia burgdorferi isolates. Immunobiology 201:406-419.[Medline]
  31. Kraiczy, P., C. Skerka, V. Brade, and P. F. Zipfel. 2001. Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect. Immun. 69:7800-7809.[Abstract/Free Full Text]
  32. Kraiczy, P., C. Skerka, M. Kirschfink, V. Brade, and P. F. Zipfel. 2001. Immune evasion of Borrelia burgdorferi by acquisition of human complement regulators FHL-1/reconectin and factor H. Eur. J. Immunol. 31:1674-1684.[CrossRef][Medline]
  33. Kraiczy, P., C. Skerka, M. Kirschfink, P. F. Zipfel, and V. Brade. 2001. Mechanism of complement resistance of pathogenic Borrelia burgdorferi isolates. Int. Immunopharmacol. 1:393-401.[CrossRef][Medline]
  34. Kraiczy, P., C. Skerka, P. F. Zipfel, and V. Brade. 2002. Complement regulator-acquiring surface proteins of Borrelia burgdorferi: a new protein family involved in complement resistance. Wien. Klin. Wochenschr. 114:568-573.[Medline]
  35. Lederer, S., C. Brenner, T. Stehle, L. Gern, R. Wallich, and M. M. Simon. 2005. Quantitative analysis of Borrelia burgdorferi gene expression in naturally (tick) infected mouse strains. Med. Microbiol. Immunol. 194:81-90.[CrossRef][Medline]
  36. Livey, I., C. P. Gibbs, R. Schuster, and F. Dorner. 1995. Evidence for lateral transfer and recombination in OspC variation in Lyme disease Borrelia. Mol. Microbiol. 18:257-269.[CrossRef][Medline]
  37. Lünemann, J. D., S. Zarmas, S. Priem, J. Franz, R. Zschenderlein, E. Aberer, R. Klein, L. Schouls, G. R. Burmester, and A. Krause. 2001. Rapid typing of Borrelia burgdorferi sensu lato in specimens from patients with different manifestations of Lyme borreliosis. J. Clin. Microbiol. 39:1130-1133.[Abstract/Free Full Text]
  38. McDowell, J. V., K. M. Hovis, H. Zhang, E. Tran, J. Lankford, and R. T. Marconi. 2006. Evidence that BBA68 protein (BbCRASP-1) of the Lyme disease spirochetes does not contribute to factor H-mediated immune evasion in humans and other animals. Infect. Immun. 74:3030-3034.[Abstract/Free Full Text]
  39. McDowell, J. V., J. Wolfgang, E. Tran, M. S. Metts, D. Hamilton, and R. T. Marconi. 2003. Comprehensive analysis of the factor H binding capabilities of Borrelia species associated with Lyme disease: delineation of two distinct classes of factor H binding proteins. Infect. Immun. 71:3597-3602.[Abstract/Free Full Text]
  40. Metts, M. S., J. V. McDowell, M. Theisen, P. R. Hansen, and R. T. Marconi. 2003. Analysis of the OspE determinants involved in binding of factor H and OspE-targeting antibodies elicited during Borrelia burgdorferi infection. Infect. Immun. 71:3587-3596.[Abstract/Free Full Text]
  41. Miller, J. C., N. El-Hage, K. Babb, and B. Stevenson. 2000. Borrelia burgdorferi B31 Erp proteins that are dominant immunoblot antigens of animals infected with isolate B31 are recognized by only a subset of human Lyme disease patient sera. J. Clin. Microbiol. 38:1569-1574.[Abstract/Free Full Text]
  42. Miller, J. C., and B. Stevenson. 2006. Borrelia burgdorferi erp genes are expressed at different levels within tissues of chronically infected mammalian hosts. Int. J. Med. Microbiol. 296(S1):185-194.[CrossRef][Medline]
  43. Miller, J. C., and B. Stevenson. 2003. Immunological and genetic characterization of Borrelia burgdorferi BapA and EppA proteins. Microbiology 149:1113-1125.[Abstract/Free Full Text]
  44. Miller, J. C., K. von Lackum, K. Babb, J. D. McAlister, and B. Stevenson. 2003. Temporal analysis of Borrelia burgdorferi Erp protein expression throughout the mammal-tick infectious cycle. Infect. Immun. 71:6943-6952.[Abstract/Free Full Text]
  45. Miller, J. C., K. von Lackum, M. E. Woodman, and B. Stevenson. 2006. Detection of Borrelia burgdorferi gene expression during mammalian infection using transcriptional fusions that produce green fluorescent protein. Microb. Pathog. 41:43-47.[CrossRef][Medline]
  46. O'Connell, S., M. Granstrom, J. S. Gray, and G. Stanek. 1998. Epidemiology of European Lyme borreliosis. Zentralbl. Bakteriol. 287:229-240.[Medline]
  47. Ohlenbusch, A., F.-R. Matuschka, D. Richter, H.-J. Christen, R. Thomssen, A. Spielman, and H. Eiffert. 1996. Etiology of the acrodermatitis chronica atrophicans lesion in Lyme disease. J. Infect. Dis. 174:421-423.[Medline]
  48. Piesman, J., T. M. Mather, R. J. Sinsky, and A. Spielman. 1987. Duration of tick attachment and Borrelia burgdorferi transmission. J. Clin. Microbiol. 25:557-558.[Abstract/Free Full Text]
  49. Postic, D., N. Marti Ras, R. S. Lane, M. Hendson, and G. Baranton. 1998. Expanded diversity among California Borrelia isolates and description of Borrelia bissettii sp. nov. (formerly Borrelia group DN127). J. Clin. Microbiol. 36:3497-3504.[Abstract/Free Full Text]
  50. Preac-Mursic, V., B. Wilske, and G. Schierz. 1986. European Borrelia burgdorferi isolated from humans and ticks: culture conditions and antibiotic susceptibility. Zentralbl. Bakteriol. Hyg. A 263:112-118.
  51. Qiu, W. G., S. E. Schutzer, J. F. Bruno, O. Attie, Y. Xu, J. J. Dunn, S. R. Casjens, and B. J. Luft. 2004. Genetic exchange and plasmid transfers in Borrelia burgdorferi sensu stricto revealed by three-way genome comparisons and multilocus sequence typing. Proc. Natl. Acad. Sci. USA 101:14150-14155.[Abstract/Free Full Text]
  52. Richter, D., D. B. Schlee, R. Allgöwer, and F.-R. Matuschka. 2004. Relationships of a novel Lyme disease spirochete, Borrelia spielmani sp. nov., with its hosts in central Europe. Appl. Environ. Microbiol. 70:6414-6419.[Abstract/Free Full Text]
  53. Rogers, E. A., and R. T. Marconi. 2007. Delineation of species-specific binding properties of the CspZ protein (BBH06) of Lyme disease spirochetes: evidence for new contributions to the pathogenesis of Borrelia spp. Infect. Immun. 75:5272-5281.[Abstract/Free Full Text]
  54. Rossmann, E., V. Kitiratschky, H. Hofmann, P. Kraiczy, M. M. Simon, and R. Wallich. 2006. Borrelia burgdorferi complement regulator-acquiring surface protein 1 of the Lyme disease spirochetes is expressed in humans and induces antibody responses restricted to nondenatured structural determinants. Infect. Immun. 74:7024-7028.[Abstract/Free Full Text]
  55. Ryffel, K., O. Péter, B. Rutti, A. Suard, and E. Dayer. 1999. Scored antibody reactivity determined by immunoblotting shows an association between clinical manifestations and presence of Borrelia burgdorferi sensu stricto, B. garinii, B. afzelii, and B. valaisiana in humans. J. Clin. Microbiol. 37:4086-4092.[Abstract/Free Full Text]
  56. Schulze, R. J., and W. R. Zückert. 2006. Borrelia burgdorferi lipoproteins are secreted to the outer surface by default. Mol. Microbiol. 59:1473-1484.[CrossRef][Medline]
  57. Schwan, T. G., W. Burgdorfer, and C. F. Garon. 1988. Changes in infectivity and plasmid profile of the Lyme disease spirochete, Borrelia burgdorferi, as a result of in vitro cultivation. Infect. Immun. 56:1831-1836.[Abstract/Free Full Text]
  58. Schwan, T. G., W. Burgdorfer, M. E. Schrumpf, and R. H. Karstens. 1988. The urinary bladder, a consistent source of Borrelia burgdorferi in experimentally infected white-footed mice (Peromyscus leucopus). J. Clin. Microbiol. 26:893-895.[Abstract/Free Full Text]
  59. Schwan, T. G., J. Piesman, W. T. Golde, M. C. Dolan, and P. A. Rosa. 1995. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc. Natl. Acad. Sci. USA 92:2909-2913.[Abstract/Free Full Text]
  60. Schwan, T. G., M. E. Schrumpf, R. H. Karstens, J. R. Clover, J. Wong, M. Daugherty, M. Struthers, and P. A. Rosa. 1993. Distribution and molecular analysis of Lyme disease spirochetes, Borrelia burgdorferi, isolated from ticks throughout California. J. Clin. Microbiol. 31:3096-3108.[Abstract/Free Full Text]
  61. Setubal, J. C., M. Reis, J. Matsunaga, and D. A. Haake. 2006. Lipoprotein computational prediction in spirochaetal genomes. Microbiology 152:113-121.[Abstract/Free Full Text]
  62. Stanek, G., and F. Strle. 2003. Lyme borreliosis. Lancet 362:1639-1647.[CrossRef][Medline]
  63. Steere, A. C., R. L. Grodzicki, A. N. Kornblatt, J. E. Craft, A. G. Barbour, W. Burgdorfer, G. P. Schmid, E. Johnson, and S. E. Malawista. 1983. The spirochetal etiology of Lyme disease. N. Engl. J. Med. 308:733-740.[Abstract]
  64. Stevenson, B., and S. W. Barthold. 1994. Expression and sequence of outer surface protein C among North American isolates of Borrelia burgdorferi. FEMS Microbiol. Lett. 124:367-372.[CrossRef][Medline]
  65. Stevenson, B., J. L. Bono, T. G. Schwan, and P. Rosa. 1998. Borrelia burgdorferi Erp proteins are immunogenic in mammals infected by tick bite, and their synthesis is inducible in cultured bacteria. Infect. Immun. 66:2648-2654.[Abstract/Free Full Text]
  66. Stevenson, B., T. Bykowski, A. E. Cooley, K. Babb, J. C. Miller, M. E. Woodman, K. von Lackum, and S. P. Riley. 2006. The Lyme disease spirochete Erp lipoprotein family: structure, function and regulation of expression, p. 354-372. In F. C. Cabello, H. P. Godfrey, and D. Hulinska (ed.), Molecular biology of spirochetes. IOS Press, Amsterdam, The Netherlands.
  67. Stevenson, B., N. El-Hage, M. A. Hines, J. C. Miller, and K. Babb. 2002. Differential binding of host complement inhibitor factor H by Borrelia burgdorferi Erp surface proteins: a possible mechanism underlying the expansive host range of Lyme disease spirochetes. Infect. Immun. 70:491-497.[Abstract/Free Full Text]
  68. Terekhova, D., R. Iyer, G. P. Wormser, and I. Schwartz. 2006. Comparative genome hybridization reveals substantial variation among clinical isolates of Borrelia burgdorferi sensu stricto with different pathogenic properties. J. Bacteriol. 188:6124-6134.[Abstract/Free Full Text]
  69. Theisen, M., B. Frederiksen, A.-M. Lebech, J. Vuust, and K. Hansen. 1993. Polymorphism in ospC gene of Borrelia burgdorferi and immunoreactivity of OspC protein: implications for taxonomy and for use of OspC protein as a diagnostic antigen. J. Clin. Microbiol. 31:2570-2576.[Abstract/Free Full Text]
  70. Thompson, J. D., T. J. Gibson, F. Plewniak, F. Jeanmougin, and D. G. Higgins. 1997. The Clustal X window interface: flexible strategies for multiple sequence alignment aided by quality analyses tools. Nucleic Acids Res. 24:4876-4882.
  71. van Dam, A. P., H. Kuiper, K. Vos, A. Widjojokusumo, B. M. de Jongh, L. Spanjaard, A. C. P. Ramselaar, M. D. Kramer, and J. Dankert. 1993. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin. Infect. Dis. 17:708-717.[Medline]
  72. von Lackum, K., J. C. Miller, T. Bykowski, S. P. Riley, M. E. Woodman, V. Brade, P. Kraiczy, B. Stevenson, and R. Wallich. 2005. Borrelia burgdorferi regulates expression of complement regulator-acquiring surface protein 1 during the mammal-tick infection cycle. Infect. Immun. 73:7398-7405.[Abstract/Free Full Text]
  73. Wallich, R., C. Helmes, U. E. Schaible, Y. Lobet, S. E. Moter, M. D. Kramer, and M. M. Simon. 1992. Evaluation of genetic divergence among Borrelia burgdorferi isolates by use of OspA, fla, HSP60, and HSP70 gene probes. Infect. Immun. 60:4856-4866.[Abstract/Free Full Text]
  74. Wallich, R., S. E. Moter, M. M. Simon, K. Ebnet, A. Heiberger, and M. D. Kramer. 1990. The Borrelia burgdorferi flagellum-associated 41-kilodalton antigen (flagellin): molecular cloning, expression, and amplification of the gene. Infect. Immun. 58:1711-1719.[Abstract/Free Full Text]
  75. Wang, G., C. Ojaimi, R. Iyer, V. Saksenberg, S. A. McClain, G. P. Wormser, and I. A. Schwartz. 2001. Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice. Infect. Immun. 69:4303-4312.[Abstract/Free Full Text]
  76. Wang, G., A. P. van Dam, and J. Dankert. 1999. Phenotypic and genetic characterization of a novel Borrelia burgdorferi sensu lato isolate from a patient with Lyme borreliosis. J. Clin. Microbiol. 37:3025-3028.[Abstract/Free Full Text]
  77. Wang, G., A. P. van Dam, I. Schwartz, and J. Dankert. 1999. Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implications. Clin. Microbiol. Rev. 12:633-653.[Abstract/Free Full Text]
  78. Wang, I.-N., D. E. Dykhuizen, W. Qiu, J. J. Dunn, E. M. Bosler, and B. J. Luft. 1999. Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto. Genetics 151:15-30.[Abstract/Free Full Text]
  79. Wilske, B., V. Preac-Mursic, S. Jauris, A. Hofmann, I. Pradel, E. Soutschek, E. Schwab, G. Will, and G. Wanner. 1993. Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi. Infect. Immun. 61:2182-2191.[Abstract/Free Full Text]
  80. Woodman, M. E., A. E. Cooley, J. C. Miller, J. J. Lazarus, K. Tucker, T. Bykowski, M. Botto, J. Hellwage, R. M. Wooten, and B. Stevenson. 2007. Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infection. Infect. Immun. 75:3131-3139.[Abstract/Free Full Text]
  81. Wormser, G. P., D. Liveris, J. Nowakowski, R. B. Nadelman, L. F. Cavaliere, D. McKenna, D. Holmgren, and I. Schwartz. 1999. Association of specific subtypes of Borrelia burgdorferi with hematogenous dissemination in early Lyme disease. J. Infect. Dis. 180:720-725.[CrossRef][Medline]
  82. Xu, Y., and R. C. Johnson. 1995. Analysis and comparison of plasmid profiles of Borrelia burgdorferi sensu lato strains. J. Clin. Microbiol. 33:2679-2685.[Abstract]
  83. Zückert, W. R. 2007. Laboratory maintenance of Borrelia burgdorferi, p. 12C.1.1-12C.1.10. In R. T. Coico, T. F. Kowalik, J. Quarles, B. Stevenson, and R. Taylor (ed.), Current protocols in microbiology. J. Wiley and Sons, Hoboken, NJ.

Clinical and Vaccine Immunology, March 2008, p. 484-491, Vol. 15, No. 3
1071-412X/08/$08.00+0     doi:10.1128/CVI.00415-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00415-07v1
15/3/484    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Kraiczy, P.
Right arrow Articles by Stevenson, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraiczy, P.
Right arrow Articles by Stevenson, B.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS